Adeno-associated virus (AAV) mediated advanced therapeutic interventions for inherited and non-inherited cardiac disorders
- 1 March 2026
- journal article
- review article
- Published by SAGE Publications in Journal of the Renin-Angiotensin-Aldosterone System
- Vol. 27
Abstract
Introduction: Cardiovascular diseases remain the leading cause of global morbidity and mortality, driven by a complex interplay of inherited and acquired factors that limit the long-term effectiveness of conventional pharmacological, surgical, and device-based therapies. Recent advances in gene therapy have positioned adeno-associated virus (AAV) vectors as a promising platform for addressing the molecular determinants of both inherited and non-inherited cardiac disorders. Owing to their favourable safety profile, low pathogenicity, sustained transgene expression, and broad tissue tropism, AAV vectors have evolved as the most comprehensively evaluated viral delivery system in cardiovascular gene therapy. Method: This classical review was compiled after a comprehensive literature search of major scientific databases, including PubMed, Scopus, and Web of Science, using keywords related to adeno-associated virus, therapies, inherited and non-inherited cardiac disorders. This review provides a comprehensive synthesis of the biological properties of AAV vectors, with emphasis on serotype-specific cardiac tropism, receptor usage, immunogenicity, and durability of gene expression. We critically assess preclinical and clinical evidence supporting AAV-mediated gene delivery across a spectrum of cardiac conditions, including heart failure, cardiomyopathies, ischemic heart disease, and inherited arrhythmias, highlighting both therapeutic successes and translational limitations. Conclusions: This review highlights the current delivery strategies, genetic cargoes, and emerging genome-editing approaches, which are discussed in the context of efficacy and safety. Key challenges-such as pre-existing immunity, dose-dependent toxicity, off-target transduction, manufacturing scalability, regulatory constraints, and clinical trial design-are analysed to delineate barriers to widespread clinical adoption. Finally, we outline future directions focused on rational capsid engineering, tissue-specific targeting, improved manufacturing pipelines, and optimized clinical strategies required to advance AAV-based gene therapy toward durable and accessible treatments for cardiac diseases.Keywords
This publication has 217 references indexed in Scilit:
- Effect of Intracoronary Administration of AAV1/SERCA2a on Ventricular Remodelling in Patients with Advanced Systolic Heart Failure: Results from the Agent-Hf Randomized Phase 2 TrialEuropean Journal of Heart Failure, 2017
- Manufacturing of recombinant adeno‐associated viruses using mammalian expression platformsBiotechnology Journal, 2017
- Gene delivery methods in cardiac gene therapyThe Journal of Gene Medicine, 2011
- AAV serotype 1 mediates more efficient gene transfer to pig myocardium than AAV serotype 2 and plasmidThe Journal of Gene Medicine, 2007
- Therapeutic level of functional human alpha 1 antitrypsin (hAAT) secreted from murine muscle transduced by adeno‐associated virus (rAAV1) vectorThe Journal of Gene Medicine, 2006
- Catheter-mediated subselective intracoronary gene delivery to the rabbit heart: introduction of a novel methodThe Journal of Gene Medicine, 2005
- Catheter-mediated delivery of adenoviral vectors expressing β-adrenergic receptor kinase C-terminus inhibits intimal hyperplasia and luminal stenosis in rabbit iliac arteriesThe Journal of Gene Medicine, 2004
- Several Log Increase in Therapeutic Transgene Delivery by Distinct Adeno-Associated Viral Serotype VectorsMolecular Therapy, 2000
- Efficient in vivo catheter-based pericardial gene transfer mediated by adenoviral vectorsClinical Cardiology, 1999
- Structure, Sequence, and Function Correlations among ParvovirusesVirology, 1993